Status:
COMPLETED
Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions:
Chronic Myeloid Leukaemia
Eligibility:
All Genders
18+ years
Brief Summary
The GIMEMA CML Working Party promotes an observational (retrospective and perspective) study of Imatinib-resistant or intolerant CML patients treated with Nilotinib in Italy. Enrollment will include a...
Detailed Description
Follow-up is required until the end of treatment for the purposes of the study for all patients by standard hematologic, cytogenetic and molecular criteria. This study will not contemplate any additio...
Eligibility Criteria
Inclusion
- Adult patients with Imatinib resistant (failure + suboptimal) or intolerant chronic myeloid leukaemia in all phases, who started treatment with Nilotinib between January 2005 and December 2012 in Italy.
- Adult pts treated with Nilotinib as second line therapy after Dasatinib.
Exclusion
- Patients less than 18 year old.
- Use of Nilotinib as first line treatment.
- Patients treated with Nilotinib before 2005.
Key Trial Info
Start Date :
September 13 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 24 2016
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01475110
Start Date
September 13 2012
End Date
November 24 2016
Last Update
October 25 2022
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Oncologico Basilicata
Rionero in Vulture, Potenza, Italy
2
Ospedale
Alessandria, Italy
3
S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
4
S.G. Moscati Hospital
Avellino, Italy